降脂红曲微粉治疗高脂血症临床研究

CLINICAL STUDY ON TREATMENT OF HYPERLIPEMIA WITH MICRO-POWDER OF LIPID-REDUCING HONGQU

目的:观察不同剂量降脂红曲微粉治疗高脂血症的降脂疗效和安全性,为降脂红曲的临床应用和开发提供科学依据。方法:80例高脂血症患者随机分为4组,A组(降脂红曲微粉1/2剂量组),B组(降脂红曲微粉组),C组(降脂红曲粗粉组)和D组(血脂康组)。观察治疗前后总胆固醇(TC)、三酰甘油(TG)、脂蛋白(a)[Lp(a)]、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、载脂蛋白A-I(ApoA-I)、载脂蛋白B100(ApoB100)等指标的变化。结果:用药50 d后,各组患者TC、Lp(a)水平、LDL-C/HDL-C比值、ApoB100/ApoA-I比值显著降低,ApoA-I水平显著升高,P<0.01或P<0.05;降脂红曲微粉1/2剂量组还显著降低TG,降脂红曲微粉1/2剂量组、粗粉组与血脂康组还能显著降低LDL-C,P<0.01。各组对血脂异常均有较好疗效,降脂红曲微粉1/2剂量组、血脂康组总有效率优于降脂红曲粗粉组,P<0.05。结论:降脂红曲微粉降脂疗效肯定,安全,剂量可以较常规粉碎者减半,有推广价值。

Objective： to observe the therapeutic effect and security on treatment of hyperlipemia with ditlerent doses of micro-powder of lipid-reducing hongqu （MLH）, and provide scientific proof for its clinical application and development. Methods： 80 cases of hyperlipemia patients were divided randomly into 4 groups： 21 cases in group A （MLH of 1/2 dose group）, 20 cases in group B （MLH of full dose group）, 19 cases in group C （rough-powder of lipid-reducing hongqu group） and 20 cases in group D （xuezhikang group）. To observe the changes of TC, TG, Lp（a）, LDL-C, HDL-C, ApoA-I and APOB100. Results： after 50 days of treatment, TC, Lp（a） , LDL-C/HDL-C and ApoB100/ApoA-I reduced significantly, apoA-I elevated significantly, P〈 0.01 or P〈 0.05. TG reduced in group A and LDL-C reduced in group A, C and D, P〈0.01. All the groups were effective on lipid abnormal, but total effective rate of A and D groups in reducing lipid were superior to that of C group, P〈 0.05. Conclusion： MLH is confirmatively lipid-reducing effective and safe. Its dose is half of the normal and deserves to be.used widely.